Relapses of @entity1985 are usually treated with @entity617 , initially in three to four daily divided doses. The divided-dose regimen may cause poor @entity1 compliance and greater adrenal suppression. In a prospective randomized controlled trial, we compared the efficacy of @entity617 in inducing remission of @entity1985 , when given either as a single dose or in divided doses. @entity1 with steroid-responsive @entity1985 with relapse were randomized to receive @entity617 2 mg/kg per day, either as a single morning dose or in three divided doses for 2 weeks, followed by 1.5 mg/kg on every alternate day for 4 weeks. Parents tested the urine for protein daily until remission (nil @entity644 for 3 consecutive days). The duration between initiation of treatment and achievement of remission was recorded. Of 106 @entity1 , 94 (47 each in single-dose and divided-dose groups) completed the study. The @entity1 in the two groups were similar in relation to age, sex, number of relapses in the preceding year, and blood levels of @entity1011 , albumin, and @entity165 . The mean time for achievement of remission in the single- and divided-dose groups was 8.6 and 8.5 days, respectively (P = 0.94, power 96%). After 9 months' follow-up, there were no differences in the frequency of relapses and cumulative dose of @entity617 received in the two groups. The observations suggest that @entity617 administered in a single daily dose or in divided doses is equally effective in inducing remission in @entity1 with relapsing @entity1985 .

Single- versus divided-dose @entity617 therapy for relapses of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity1985 :: ('MESH:D009404', 'Disease') :: ['nephrotic syndrome'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']
@entity1985 :: (MESH:D009404,Disease) :: ['nephrotic syndrome']
